Drug
AZD1390 clinical trials
Also written AZD1390.
- studies test it
- 9
- open now
- 3
- in phase 3
- 1
- first study started
- 2017
Keep track of what changes. Save the AZD1390 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
9 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 7
- Phase 2
- 1
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 6
AstraZeneca (3) · Children's Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · Nader Sanai (1) · Global Coalition for Adaptive Research (1) · University of Leeds (1) · The Netherlands Cancer Institute (1)
Often tested with
Tested in the same studies.
Regorafenib (1) · GDC-0084 (1) · Dianhydrogalactitol (1) · TSP-1 Activator VT1021 (1) · Troriluzole (1) · Pegargiminase (1) · Tinostamustine (1) · Olaparib (1)
Studies
Open first, then newest update. How each study uses AZD1390 is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as AZD1390
- Human ADME Study of [14C]-AZD1390Not yet recruitingPhase 1AstraZenecaNCT07643870Written as AZD1390
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingPhase 1University of LeedsNCT04550104Written as AZD1390
- A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerCompletedPhase 1AstraZenecaNCT03423628Written as AZD1390
- Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine GliomaActive, not recruitingPhase 1Children's Oncology GroupNCT06894979Written as ATM Kinase Inhibitor AZD1390
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor CancerActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05678010Written as AZD1390
- AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma PatientsActive, not recruitingEarly Phase 1Nader SanaiNCT05182905Written as AZD1390
- Sarcomas and DDR-Inhibition; a Combined Modality StudyTerminatedPhase 1The Netherlands Cancer InstituteNCT05116254Written as AZD1390 + radiotherapy
- AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy VolunteersCompletedPhase 1AstraZenecaNCT03215381Written as [11C]AZD1390
Codes
What other systems call AZD1390 · ClinicalTrials.gg INT002042
- MeSH (NLM) C000729307AZD1390One source ClinicalTrials.gov
- NCI Thesaurus C150167ATM Kinase Inhibitor AZD1390One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729307 | AZD1390 | One source ClinicalTrials.gov |
| NCI Thesaurus | C150167 | ATM Kinase Inhibitor AZD1390 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.